Skip to content

BIONOVATE TECHNOLOGIES CORP.: 10-Q filed 2020-05-15

What BIONOVATE TECHNOLOGIES CORP. reported in its quarterly report filed 2020-05-15 (fiscal Q3 2020): 17 published measures, 54 facts as tagged in accession 0001640334-20-001249.

This filing

Form
10-Q (quarterly report)
Filed
2020-05-15
Fiscal period
fiscal Q3 2020
Accession
0001640334-20-001249 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIONOVATE TECHNOLOGIES CORP. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-03-31375,703USD
At 2019-06-30332,289USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-03-31-375,703USD
At 2019-12-31-387,816USD
At 2019-09-30-361,139USD
At 2019-06-30-332,289USD
At 2019-03-31-300,602USD
At 2018-12-31-281,695USD
At 2018-09-30-251,668USD
At 2018-06-30-309,682USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-07-01 to 2020-03-31-99,083USD275
2018-07-01 to 2019-03-31-160,172USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-03-31-2,675,278USD
At 2019-06-30-2,576,195USD

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-01-01 to 2020-03-310USD/shares91
2019-07-01 to 2020-03-31-0.01USD/shares275
2019-01-01 to 2019-03-31-0.16USD/shares90
2018-07-01 to 2019-03-31-1.03USD/shares274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-2,748USD91
2019-07-01 to 2020-03-31-27,110USD275
2019-01-01 to 2019-03-31-5,392USD90
2018-07-01 to 2019-03-31-38,830USD274

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-21,600USD91
2019-07-01 to 2020-03-31-72,076USD275
2019-01-01 to 2019-03-31-19,806USD90
2018-07-01 to 2019-03-31-121,174USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-03-31375,703USD
At 2019-06-30332,289USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-03-3121,757USD
At 2019-06-3022,434USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-03-312,748USD91
2019-07-01 to 2020-03-3127,110USD275
2019-01-01 to 2019-03-315,392USD90
2018-07-01 to 2019-03-3138,830USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-03-3159,423,598shares
At 2019-06-30155,798shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-03-312,293,633USD
At 2019-06-302,243,891USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2020-03-31-375,703USD
At 2019-06-30-332,289USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-03-31116,892USD
At 2019-06-3075,041USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-24,138USD91
2019-10-01 to 2019-12-31-45,569USD92
2019-07-01 to 2019-09-30-29,376USD92
2019-01-01 to 2019-03-31-25,334USD90
2018-10-01 to 2018-12-31-47,329USD92
2018-07-01 to 2018-09-30-87,509USD92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-03-31875USD90
2018-07-01 to 2019-03-315,805USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-03-31-21,390USD91
2019-07-01 to 2020-03-31-71,973USD275
2019-01-01 to 2019-03-31-19,942USD90
2018-07-01 to 2019-03-31-121,342USD274

Inspect the source

Entity
BIONOVATE TECHNOLOGIES CORP. / CIK 0001575420
Captured
SEC response SHA-256
3a7f453b16552a566daef46e9f3eab08e75589223c6b3f8546d05522bd03527a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001575420.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))